Access our archived eMedical Forum Webcasts, which are available for your viewing at any time.
Please sign in using the form to the left to access this service.
Important Product Information
IMPORTANT INFORMATION:
SINGULAIR is indicated for the relief of symptoms of allergic rhinitis (seasonal allergic rhinitis in adults and children 2 years and older and perennial allergic rhinitis in adults and children 6 months and older).
In clinical trials, SINGULAIR was generally well tolerated, with a safety profile similar to that of placebo. Adverse events varied by age. The most commonly reported adverse events, occurring at a frequency of >1% and at an incidence greater than placebo, regardless of causality assessment, were sinusitis, upper respiratory infection, sinus headache, cough, epistaxis, headache, otitis media, pharyngitis, and increased ALT.
SINGULAIR is contraindicated in patients with hypersensitivity to any component of the product.
COZAAR and HYZAAR are registered trademarks of E.I. du Pont de Nemours and Company, Wilmington, Delaware, USA
FOSAMAX PLUS D is a trademark of Merck & Co., Inc.
VYTORIN and ZETIA are registered trademarks of MSP Singapore Company, LLC. View the Merck/Schering-Plough privacy policy.
All other brand names are registered trademarks of Merck & Co., Inc.
MerckServices and MerckSource are registered trademarks of Merck & Co., Inc.
MerckProductServices and MerckMedicus are trademarks of Merck & Co., Inc.
Contact Us
Ask a Product-Related Question or Report an Adverse Event
Let us assist you with information and services related to Merck and its products. Get Started
Live Product Discussion About SINGULAIR® (montelukast sodium)
We're ready when you are with the latest product information and resources for SINGULAIR. Begin Your Discussion
requires a 
requires a 
SINGULAIR® (montelukast sodium) For Symptoms of Allergic Rhinitis
